Magnesium Sulfate Has No Established Role in Intracerebral Hemorrhage Management
Magnesium sulfate is not recommended for routine use in intracerebral hemorrhage (ICH), as the highest-quality evidence shows no clinical benefit for hematoma expansion or functional outcomes. The only established indication for magnesium sulfate in the context of intracranial bleeding is for seizure prophylaxis and treatment in eclampsia/pre-eclampsia, not for primary ICH management 1.
Evidence from Clinical Trials
The FAST-MAG trial, which enrolled patients with acute stroke syndromes including ICH, found no reduction in hematoma expansion with magnesium sulfate treatment when analyzed by treatment group 2. In this pragmatic trial of 268 ICH patients, there was no statistical difference in hematoma volume on arrival (10.1 vs 12.4 mL, P=0.6), hematoma expansion (2.0 vs 1.5 mL, P=0.5), or functional outcomes at 90 days (59% vs 50% with mRS 3-6, P=0.5) between magnesium and placebo groups 2.
The IMASH phase 3 trial (Intravenous Magnesium sulfate for Aneurysmal Subarachnoid Hemorrhage) definitively showed no clinical benefit from magnesium infusion over placebo in aneurysmal SAH, which represents a different pathophysiology than primary ICH but was the most rigorous test of magnesium's neuroprotective effects in intracranial hemorrhage 1.
Conflicting Observational Data
While retrospective observational studies suggest associations between lower admission magnesium levels and larger hematoma volumes, greater hematoma expansion, and worse functional outcomes 3, 4, these findings have not translated into therapeutic benefit in randomized trials 2. A 2024 secondary analysis of FAST-MAG found that higher magnesium levels were associated with less hematoma expansion only in the magnesium-treated group (adjusted OR 0.64 per mg/dL), but this exploratory finding was limited by biased availability of neuroimaging data and requires prospective validation 5.
Current Guideline Recommendations
For Primary Intracerebral Hemorrhage
No major stroke guidelines recommend magnesium sulfate for ICH treatment. The 2022 AHA/ASA guidelines for spontaneous ICH management do not include magnesium therapy in their recommendations for medical management, blood pressure control, or prevention of hematoma expansion 1. The 2007 AHA/ASA ICH guidelines similarly make no mention of magnesium as a therapeutic option 1.
For Aneurysmal Subarachnoid Hemorrhage
The 2012 AHA/ASA guidelines for aneurysmal SAH explicitly state that magnesium sulfate showed no clinical benefit in the IMASH phase 3 trial, though pilot studies suggested possible reduction in delayed ischemic deficits 1. The guidelines note that while some suggestion of benefit existed in earlier meta-analyses, the definitive phase 3 trial was negative 1.
The Only Established Use: Pre-eclampsia/Eclampsia
Magnesium sulfate is recommended (Class I) for eclampsia treatment and for women with pre-eclampsia who have severe hypertension with proteinuria or neurological symptoms 1. The 2024 ESC hypertension guidelines specify dosing of 4 g IV over 5 minutes, then 1 g/h IV; or 5 g IM into each buttock, then 5 g IM every 4 hours 1. This indication is for seizure prevention/treatment in pregnancy-related hypertensive disorders, not for the intracerebral hemorrhage itself 1.
Critical Pitfalls to Avoid
Do not extrapolate pre-eclampsia/eclampsia dosing to primary ICH: The therapeutic magnesium levels for eclampsia (4-7 mEq/L) are supraphysiologic and carry risks of hypotension, respiratory depression, and cardiac toxicity 6.
Recognize that continuous magnesium sulfate administration beyond 5-7 days in pregnancy can cause fetal abnormalities, including hypocalcemia, skeletal demineralization, and osteopenia 6.
Monitor for magnesium toxicity: Loss of patellar reflexes occurs at ~10 mEq/L, with respiratory paralysis as a potential hazard; calcium gluconate or calcium chloride should be immediately available for reversal 6.
Avoid in severe renal insufficiency: Maximum dose is 20 g/48 hours with frequent serum monitoring when creatinine clearance is substantially reduced 6.
Practical Algorithm for Magnesium Use in Hemorrhagic Stroke
Step 1: Identify the type of intracranial hemorrhage
- Primary ICH → No magnesium indicated
- Aneurysmal SAH → No magnesium indicated (based on negative IMASH trial) 1
- ICH in pregnant patient with eclampsia → Proceed to Step 2
Step 2: For eclampsia with ICH, administer magnesium for seizure control
- Loading dose: 4-5 g IV in 250 mL over 15-30 minutes 6
- Maintenance: 1-2 g/hour continuous infusion 6
- Target serum level: 4-7 mEq/L (therapeutic for seizure control) 6
- Monitor patellar reflexes, respiratory rate, and urine output 6
Step 3: Manage the ICH itself according to standard guidelines
- Blood pressure control (target systolic 140-160 mmHg within 6 hours) 1
- Reversal of anticoagulation if applicable 1
- Neurosurgical consultation for hematoma evacuation if indicated 1
Future Research Considerations
The 2024 FAST-MAG secondary analysis suggesting a hemostatic effect of magnesium only in patients achieving higher serum levels requires prospective validation 5. The authors appropriately conclude that "equipoise should be maintained, and specific trials are needed" 5. Until such trials demonstrate benefit, magnesium sulfate should not be used for ICH outside of clinical trials or the specific indication of eclampsia-related seizure control 1, 2.